President Trump has enacted an executive order designed to cut drug costs for Americans by as much as 90%. This would involve aligning prices paid by government programs like Medicare with those pharmaceutical companies charge abroad.
“Other countries have been benefiting from our subsidies,” Trump remarked during the ceremony at the White House, calling the signing “one of the most significant orders.” He mentioned a significant reduction in prescription drug prices, projecting that some could fall between 50 to 90%. He stated that major pharmaceutical companies would need to comply voluntarily, or the federal government would ensure that prices match those overseas.
This policy revives Trump’s “most favored nation” approach. Experts have commented that the U.S. has been disproportionately burdened with the financial responsibilities of research and development costs, helping other nations.
Previously, Trump expressed confidence that this initiative would markedly reduce healthcare costs in the U.S., even promising substantial savings for American citizens. “The U.S. will ultimately save trillions,” he claimed on True Society Sunday.
According to White House officials, the order will combat irrational policies in foreign countries that restrict drug pricing. In about thirty days, Health and Human Services Director Robert F. Kennedy Jr. is expected to outline specific price reduction goals and initiate dialogue with the pharmaceutical industry.
Some analysts argue that foreign countries have “freeloaded” off the U.S. by keeping their drug prices artificially low, which leads pharmaceutical firms to increase costs for American consumers to cover R&D expenses.
“It’s notable that less than 5% of the U.S. population contributes to around three-quarters of global drug profits. This situation is clearly unacceptable,” a White House spokesperson explained ahead of the order.
He also emphasized that, fundamentally, the goal is equivalence in drug pricing, pointing out that U.S. patients have been effectively subsidizing healthcare in other nations.
Unlike his previous term, this order takes a more expansive approach and aims to enhance negotiation powers surrounding Medicare Part B, as reported by White House officials.
They noted that they do not anticipate a negative effect on innovation stemming from these changes. “The U.S. shouldn’t have to finance global innovations alone,” they said.
The Department of Justice and the Federal Trade Commission will be charged with tackling anti-competitive practices that inflate drug prices. Additionally, the FDA will explore importing drugs from other countries like Canada to alleviate costs for consumers, provided health and safety are not compromised.
“I know special interests may not appreciate this, but Americans will,” Trump stated, affirming that his motivation is ultimately to benefit the public. “I’m standing up to possibly the most powerful lobby – the pharmaceutical lobby.”
Officials at the White House refrained from labeling the policy as a form of price control, clarifying that the U.S. market suffers from excessive pricing for the same drugs that are much cheaper in other countries. “This isn’t merely a price adjustment; we’re aiming to restructure market dynamics,” one official elaborated.
Kennedy voiced his surprise at the executive order, describing it as a significant shift akin to what Bernie Sanders advocated for in past campaigns.
Former President Biden had previously reversed Trump’s “most favored nation” policy and criticized the new drug pricing strategy implemented under the Inflation Reduction Act.
Trump also hinted at addressing the role of “middlemen” in drug pricing, referring to pharmacy benefit managers who have faced bipartisan scrutiny but remained vague about how that would be accomplished. “We’re going to completely eliminate those intermediaries,” he declared, adding that while he was uncertain about who they were, it was clear they were profiting significantly.
